IGC Pharma
23 hedge funds and large institutions have $827K invested in IGC Pharma in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.
444% more call options, than puts
Call options by funds: $49K | Put options by funds: $9K
0% more funds holding
Funds holding: 23 → 23 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.1% less ownership
Funds ownership: 5.1% → 5% (-0.1%)
8% less capital invested
Capital invested by funds: $900K → $827K (-$72.1K)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$17K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$5K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$75 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$5 |
| 5 |
Goldman Sachs
New York
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$29.3K |
| 2 |
Jane Street
New York
|
-$5.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.39K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$60 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$37 |
IGC Hedge Fund Activity: Q2 2023 in Review
23 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q2 2023, worth a combined $827K — down 8% from $900K a quarter earlier.
Fund positioning in IGC was balanced in Q2 2023: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $17K. The largest seller was Millennium Management, cutting an estimated $29.3K.
- 23 institutional investors held IGC Pharma (IGC) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $827K of IGC Pharma stock for Q2 2023, down 8% quarter-over-quarter.
- 1 fund opened new IGC Pharma positions in Q2 2023 and 1 closed out, a net change of 0 holders.
- The largest IGC Pharma buyer in Q2 2023 was Renaissance Technologies, an estimated $17K added.
- The largest IGC Pharma seller in Q2 2023 was Millennium Management, an estimated $29.3K sold.
Based on aggregated 13F filings for Q2 2023.